REPATH LAUNCH
15 September 2026
Global
Genspect's REPATH campaign formally launched on 15 September 2026, calling for the restoration of psychiatric assessment in cases of transgender ideation. Hosts Stella O'Malley and Mia Hughes discuss what the campaign demands, why automatic gender affirmation bypasses the standard of care that exists for every comparable condition, and how a return to differential diagnosis aligns with the findings of systematic reviews published across Europe over recent years.
On 15 September 2026, Genspect formally launched REPATH — the Re-psychopathologisation Campaign — and Beyond Gender devoted its episode to unpacking what the campaign is, what it is asking for, and why it matters now. Stella O'Malley and Mia Hughes take listeners through the core argument: that transgender ideation should once again be understood within a psychiatric framework, not because gender non-conformity is itself pathological, but because distress serious enough to prompt requests for medical intervention warrants the same rigorous clinical attention applied to any other presentation of comparable complexity. The central demand of REPATH is for thorough differential diagnosis before any gender-related treatment pathway is initiated. Psychological and psychiatric assessment should, the campaign argues, replace the practice of automatic affirmation that has become standard in many gender clinics. This is not a fringe position. The independent review led by Dr Hilary Cass, published in the United Kingdom in April 2024, reached a structurally similar conclusion: that the evidence base for social and medical affirmation in under-eighteens was weak, that co-occurring mental health conditions were routinely under-explored, and that the clinical culture had moved away from the kind of open, exploratory care that good psychiatric practice requires. The timing of the REPATH launch is significant. Across Europe, national health authorities have been revisiting their guidance on paediatric gender medicine. Sweden, Finland, Denmark and Norway each moved, between 2022 and 2025, to restrict or suspend puberty blockers and cross-sex hormones for minors outside research settings, citing the same insufficiency of evidence that systematic reviews conducted by NICE, the Swedish Agency for Health Technology Assessment and other bodies had documented. In each case, the pivot was driven by exactly the kind of psychiatric and evidence-based scrutiny that REPATH is now demanding be reinstated at the level of individual clinical encounters. O'Malley, a psychotherapist with extensive experience working with young people presenting with gender distress, and Hughes, whose research work has focused on the institutions that shape gender medicine policy, are well placed to examine the campaign's clinical and political dimensions. The episode does not call for the refusal of care; it calls for care that begins with understanding. Differential diagnosis — ruling out autism, trauma, depression, anxiety, dissociation and other conditions that frequently co-occur with gender dysphoria — is standard medicine. REPATH's argument is that gender medicine removed itself from that standard and that the documented harm flowing from that removal now demands a course correction. For those following the evidence landscape, the REPATH launch represents an attempt to translate what systematic reviews have established at the population level into a principle that governs individual clinical encounters. The episode explores how that translation might work in practice, what resistance it is likely to meet from professional bodies still committed to affirmation-first protocols, and why O'Malley and Hughes regard the campaign as a necessary and overdue step toward accountable, evidence-grounded care.
